Skip to main content
SpringerLink
Log in

Immunoglobulin A Nephropathy in Children

  • Reference work entry
  • First Online:
Pediatric Nephrology

  • 2957 Accesses

Abstract

IgA nephropathy (IgAN), defined by dominant immunoglobulin A glomerular deposits, is the commonest glomerular disease in children presenting with microscopic hematuria. Its prevalence varies from 10% to 40% accounting for renal biopsy criteria and screening school programs. The pathogenetic events include mucosal production of galactose deficient IgA1, IgG autoimmune response, circulation and deposition of macromolecular IgA1 followed by complement activation, glomerular inflammation, and damage. The characteristic pathology feature is mesangial enlargement, with hypercellularity and matrix expansion. Renal pathology lesions are scored according to the Oxford Classification (mesangial hypercellularity M; endocapillary hypercellularity E; segmental glomerulosclerosis S; tubular atrophy/interstitial fibrosis T, crescents C) providing the MEST-C score. The most characteristic presentation is macroscopic hematuria associated with upper respiratory tract infections, sometimes with overt nephritic syndrome. Most children have microscopic hematuria with or without asymptomatic proteinuria, while a few have nephrotic onset. The outcome is generally favorable within the pediatric age, and up to 9% develop renal failure by 15 years. However, mild cases of IgAN in children might be missed and manifest irreversible damage only decades later. Hypertension, persistent heavy proteinuria, and reduced glomerular filtration rate at presentation and the MEST-C score provide prognostication indications. Not all children with IgAN need treatment as spontaneous remission may occur in mild cases. In children developing proteinuria angiotensin system, inhibitors are the first approach, while corticosteroids are an option for children with worsening proteinuria despite treatment or in cases with clinical and pathology features indicating active and potentially progressive IgAN.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Berger J, Hinglais N. Intercapillary deposits of IgA–IgG. J Urol Nephrol. 1968;74:694–5.

    CAS  Google Scholar 

  2. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–14.

    CAS  PubMed  Google Scholar 

  3. Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38:435–42.

    PubMed  Google Scholar 

  4. O’Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transplant. 2018;33:661–9.

    PubMed  Google Scholar 

  5. Coppo R. Pediatric IgA nephropathy in Europe. Kidney Dis. 2019;5:182–8.

    Google Scholar 

  6. Coppo R, Robert T. IgA nephropathy in children and in adults: two separate entities or the same disease? J Nephrol. 2020; https://doi.org/10.1007/s40620-020-00725-0.

  7. Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, et al, Committee for Standardization of Renal Pathological Diagnosis, Committee for Kidney Disease Registry, Japanese Society of Nephrology. Japan Renal Biopsy Registry and Japan Kidney Disease Registry: committee report for 2009 and 2010. Clin Exp Nephrol. 2013;17:155–73.

    Google Scholar 

  8. Cho BS, Hahn WH, Cheong HI, Lim I, Ko CW, Kim SY, Lee DY, et al. A nationwide study of mass urine screening tests on Korean school children and implications for chronic kidney disease management. Clin Exp Nephrol. 2013;17:205–10.

    CAS  PubMed  Google Scholar 

  9. Rodrigues JC, Haas M, Reich H. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA. Prognostic indicators in children with IgA nephropathy – report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 1994;8(1):15–20.

    CAS  PubMed  Google Scholar 

  11. Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, et al. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol. 2017;32:139–50.

    PubMed  Google Scholar 

  12. Julian BA, Quiggins PA, Thompson JS, Woodford SY, Gleason K, Wyatt RJ. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med. 1985;312(4):202–8.

    CAS  PubMed  Google Scholar 

  13. Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, et al. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis. 1999;33(5):857–65.

    CAS  PubMed  Google Scholar 

  14. Shimomura M, Yoshikawa N, Iijima K, Nakamura H, Miyazaki M, Sakai H. Polymorphism of immunoglobulin heavy chain switch region gene in children with severe IgA nephropathy. Clin Nephrol. 1995;43(4):211–5.

    CAS  PubMed  Google Scholar 

  15. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, et al. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009;22(1):152–9.

    CAS  PubMed  Google Scholar 

  16. Lin J, Huang Y, Zhang X, Chen J, Sheng H. Association of miR-146a rs2910164 with childhood IgA nephropathy. Pediatr Nephrol. 2014;29:1979–86.

    PubMed  Google Scholar 

  17. Vuong MT, Lundberg S, Gunnarsson I, Wramner L, Seddighzadeh M, Hahn-Zoric M, et al. Genetic variation in the transforming growth factor-beta1 gene is associated with susceptibility to IgA nephropathy. Nephrol Dial Transplant. 2009;24(10):3061–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Tanaka R, Iijima K, Xu H, Inoue Y, Murakami R, Shirakawa T, et al. Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy. Am J Kidney Dis. 1999;34(2):289–95.

    CAS  PubMed  Google Scholar 

  19. Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010;21(10):1791–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43(4):321–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Yu XQ, Li M, Zhang H, Low HQ, Wei X, Wang JQ, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet. 2012;44(2):178–82.

    CAS  Google Scholar 

  22. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8:e1002765.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46:1187–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Coppo R, Camilla R, Alfarano A, Balegno S, Mancuso D, Peruzzi L, et al. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int. 2009;75(5):536–41.

    CAS  PubMed  Google Scholar 

  25. Xie J, Kiryluk K, Li Y, Mladkova N, Zhu L, Hou P, et al. Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J Am Soc Nephrol. 2016;27:3187–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhu L, Zhai Y, Wang F, Hou P, Lv J, Xu D, et al. Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J Am Soc Nephrol. 2015;26:1195–204.

    CAS  PubMed  Google Scholar 

  27. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol. 2010;5:2363–72.

    PubMed  Google Scholar 

  28. Kerr MA. The structure and function of human IgA. Biochem J. 1990;271:285–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Allen AC, Bailey EM, Barratt J, Buck KS, Feehally J. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol. 1999;10(8):1763–71.

    CAS  PubMed  Google Scholar 

  30. Hiki Y, Tanaka A, Kokubo T, Iwase H, Nishikido J, Hotta K, et al. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Am Soc Nephrol. 1998;9(4):577–82.

    CAS  PubMed  Google Scholar 

  31. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int. 2004;65:1544–7.

    CAS  PubMed  Google Scholar 

  32. Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, et al. Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res. 2008;31:29–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Suzuki H, Moldoveanu Z, Hall S, Brown R, Julian BA, Wyatt RJ, et al. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1. Contrib Nephrol. 2007;157:129–33.

    CAS  PubMed  Google Scholar 

  34. Rifai A, Schena FP, Montinaro V, Mele M, D’Addabbo A, Nitti L, et al. Clearance kinetics and fate of macromolecular IgA in patients with IgA nephropathy. Lab Investig. 1989;61(4):381–8.

    CAS  PubMed  Google Scholar 

  35. Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, et al. Serum IgA and macromolecular IgA reacting with mesangial matrix components. Contrib Nephrol. 1993;104:162–71.

    CAS  PubMed  Google Scholar 

  36. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71(11):1148–54.

    CAS  PubMed  Google Scholar 

  38. Coppo R. Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol. 2017;32(5):725–31.

    PubMed  Google Scholar 

  39. Kiryluk K, Moldoveanu Z, Sanders J, Eison TM, Suzuki H, Julian BA, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int. 2011;80(1):79–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Monteiro RC. Recent advances in the physiopathology of IgA nephropathy. Nephrol Ther. 2018;14(Suppl 1):S1–8.

    PubMed  Google Scholar 

  41. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang P, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med. 2012;209:793–806.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Coppo R, Fonsato V, Balegno S, Ricotti E, Loiacono E, Camilla R, et al. Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int. 2010;77(5):417–27.

    CAS  PubMed  Google Scholar 

  43. Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Tam KY, et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant. 2009;24(1):62–72.

    CAS  PubMed  Google Scholar 

  44. Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, et al. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis. 1993;21:593–602.

    CAS  PubMed  Google Scholar 

  45. Maillard N, Wyatt RJ, Julian BA. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26:1503–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Daha MR, van Kooten C. Role of complement in IgA nephropathy. J Nephrol. 2016;29:1–4.

    CAS  PubMed  Google Scholar 

  47. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001;167:2861–8.

    CAS  PubMed  Google Scholar 

  48. Coppo R. C4d deposits in IgA nephropathy: where does complement activation come from? Pediatr Nephrol. 2017;32(7):1097–101.

    PubMed  Google Scholar 

  49. Espinosa M, Ortega R, Sánchez M, Segarra A, Salcedo MT, González F, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014;9:897–904.

    PubMed  PubMed Central  Google Scholar 

  50. Fabiano RCG, de Almeida Araújo S, Bambirra EA, Oliveira EA, Simões E, Silva AC, Pinheiro SVB. Mesangial C4d deposition may predict progression of kidney disease in pediatric patients with IgA nephropathy. Pediatr Nephrol. 2017;32:1211–20.

    PubMed  Google Scholar 

  51. Chua JS, Zandbergen M, Wolterbeek R, Baelde HJ, van Es LA, de Fijter JW, et al. Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. Mod Pathol. 2019;32(8):1147–57.

    CAS  PubMed  Google Scholar 

  52. Trimarchi H, Coppo R. Glomerular endothelial activation, C4d deposits and microangiopathy in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2019;2019:gfz241. https://doi.org/10.1093/ndt/gfz241.

    Article  CAS  Google Scholar 

  53. Coppo R, Peruzzi L, Loiacono E, Bergallo M, Krutova A, Russo ML, et al. Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy. Nephrol Dial Transplant. 2019;34(4):587–96.

    CAS  PubMed  Google Scholar 

  54. Zhang YM, Zhang H. Insights into the role of mucosal immunity in IgA nephropathy. Clin J Am Soc Nephrol. 2018;13(10):1584–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest. 2014;124(6):2325–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Buck KS, Smith AC, Molyneux K, El-Barbary H, Feehally J, Barratt J. B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int. 2008;73:1128–36.

    CAS  PubMed  Google Scholar 

  57. Tomino Y, Sakai H, Endoh M, Suga T, Miura M, Kaneshige H, et al. Cross-reactivity of IgA antibodies between renal mesangial areas and nuclei of tonsillar cells in patients with IgA nephropathy. Clin Exp Immunol. 1983;51(3):605–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, et al. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant. 2012;27(3):1090–7.

    CAS  PubMed  Google Scholar 

  59. Vergano L, Loiacono E, Albera R, Coppo R, Camilla R, Peruzzi L, et al. Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy? J Nephrol. 2015;28(1):51–8.

    CAS  PubMed  Google Scholar 

  60. Coppo R. The gut-renal connection in IgA nephropathy. Semin Nephrol. 2018;38:504–12.

    CAS  PubMed  Google Scholar 

  61. Pasternack A, Collin P, Mustonen J, Reunala T, Rantala I, Laurila K, et al. Glomerular IgA deposits in patients with celiac disease. Clin Nephrol. 1990;34(2):56–60.

    CAS  PubMed  Google Scholar 

  62. McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio E, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest. 2011;121(10):3991–4002.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535(7610):65–74.

    CAS  PubMed  Google Scholar 

  64. De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One. 2014;9(6):e99006.

    PubMed  PubMed Central  Google Scholar 

  65. Davin JC, Forget P, Mahieu PR. Increased intestinal permeability to (51 Cr) EDTA is correlated with IgA immune complex-plasma levels in children with IgA-associated nephropathies. Acta Paediatr Scand. 1988;77:118–24.

    CAS  PubMed  Google Scholar 

  66. Kovács T, Kun L, Schmelczer M, Wagner L, Davin JC, Nagy J. Do intestinal hyperpermeability and the related food antigens play a role in the progression of IgA nephropathy? Study of intestinal permeability. Am J Nephrol. 1966;16:500–5.

    Google Scholar 

  67. Nagy J, Scott H, Brandtzaeg P. Antibodies to dietary antigens in IgA nephropathy. Clin Nephrol. 1988;29:275–9.

    CAS  PubMed  Google Scholar 

  68. Jiang J, Wang XX, Shen PC, Sun C, He LQ. Clinical investigation on mucosal immune system in IgA nephropathy patients. J Dalian Med Univ. 2016;38:558–61.

    Google Scholar 

  69. Qin W, Zhong X, Fan JM, Liu XR, Li Z, Ma XY, et al. Effect of methylation modification on the expression of Cosmc gene in peripheral B lymphocyte of IgA nephropathy patients. Sichuan Da Xue Xue Bao Yi Xue Ban. 2011;42(6):762–5.

    CAS  PubMed  Google Scholar 

  70. Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, et al. Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schonlein purpura and primary IgA nephropathy. Pediatr Nephrol. 2014;29:1545–51.

    PubMed  Google Scholar 

  71. Emancipator SN, Gallo GR, Lamm ME. Experimental IgA nephropathy induced by oral immunization. J Exp Med. 1983;157(2):572–82.

    CAS  PubMed  Google Scholar 

  72. Coppo R, Mazzucco G, Martina G, Roccatello D, Amore A, Novara R, et al. Gluten-induced experimental IgA glomerulopathy. Lab Investig. 1989;60(4):499–506.

    CAS  PubMed  Google Scholar 

  73. Coppo R, Basolo B, Rollino C, Roccatello D, Martina G, Amore A, et al. Dietary gluten and primary IgA nephropathy. N Engl J Med. 1986;315(18):1167–8.

    CAS  PubMed  Google Scholar 

  74. Papista C, Lechner S, Ben Mkaddem S, LeStang MB, Abbad L, Bex-Coudrat J, et al. Gluten exacerbates IgA nephropathy in humanized mice through gliadin–CD89 interaction. Kidney Int. 2015;88(2):276–85.

    CAS  PubMed  Google Scholar 

  75. Coppo R. The gut–kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr Nephrol. 2018;33(1):53–61.

    PubMed  Google Scholar 

  76. Yoshikawa N, Ito H, Nakamura H. IgA nephropathy in children from Japan. Clinical and pathological features. Child Nephrol Urol. 1988;9(4):191–9.

    PubMed  Google Scholar 

  77. Miura M, Tomino Y, Yagame M, Endoh M, Suga T, Nomoto Y, et al. Immunofluorescent studies on alpha 2-plasmin inhibitor (alpha 2-PI) in glomeruli from patients with IgA nephropathy. Clin Exp Immunol. 1985;62(2):380–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Yoshikawa N, Ito H, Nakahara C, Yoshiara S, Yoshiya K, Matsuo T, et al. Glomerular electron dense deposits in childhood IgA nephropathy. Virchows Arch A Pathol Anat Histopathol. 1985;406(1):33–43.

    CAS  PubMed  Google Scholar 

  79. Andreoli SP, Yum MN, Bergstein JM. IgA nephropathy in children: significance of glomerular basement membrane deposition of IgA. Am J Nephrol. 1986;6(1):28–33.

    CAS  PubMed  Google Scholar 

  80. Yoshikawa N, Ito H, Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron. 1992;60(1):60–7.

    CAS  PubMed  Google Scholar 

  81. Alvarado AS, Andeen NK, Brodsky S, Hinton A, Nadasdy T, Alpers CE, et al. Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2018;33(7):1168–75.

    CAS  PubMed  Google Scholar 

  82. Yoshikawa N, Yoshiara S, Yoshiya K, Matsuo T, Okada S. Lysis of the glomerular basement membrane in children with IgA nephropathy and Henoch-Shonlein nephritis. J Pathol. 1986;150(2):119–26.

    CAS  PubMed  Google Scholar 

  83. Yoshikawa N, Iijima K, Maehara K, Yoshiara S, Yoshiya K, Matsuo T, et al. Mesangial changes in IgA nephropathy in children. Kidney Int. 1987;32(4):585–9.

    CAS  PubMed  Google Scholar 

  84. Zimmerman SW, Burkholder PM. Immunoglobulin A nephropathy. Arch Intern Med. 1975;135(9):1217–23.

    CAS  PubMed  Google Scholar 

  85. Hara M, Endo Y, Nihei H, Hara S, Fukushima O, Mimura N. IgA nephropathy with subendothelial deposits. Virchows Arch A Pathol Anat Histol. 1980;386(3):249–63.

    CAS  PubMed  Google Scholar 

  86. Suzuki J, Yoshikawa N, Nakamura H. A quantitative analysis of the mesangium in children with IgA nephropathy: sequential study. J Pathol. 1990;161(1):57–64.

    CAS  PubMed  Google Scholar 

  87. Nicholls KM, Fairley KF, Dowling JP, Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984;53(210):227–50.

    CAS  PubMed  Google Scholar 

  88. D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24(3):179–96.

    PubMed  Google Scholar 

  89. Wu Q, Tanaka H, Hirukawa T, Endoh M, Fukagawa M. Characterization and quantification of proliferating cell patterns in endocapillary proliferation. Nephrol Dial Transplant. 2012;27(8):3234–41.

    CAS  PubMed  Google Scholar 

  90. Ikezumi Y, Suzuki T, Karasawa T, Hasegawa H, Yamada T, Imai N, et al. Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology. 2011;58(2):198–210.

    PubMed  Google Scholar 

  91. Droz D. Natural history of primary glomerulonephritis with mesangial deposits of IgA. Contrib Nephrol. 1976;2:150–6.

    Google Scholar 

  92. Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine. 1994;73(2):79–102.

    CAS  PubMed  Google Scholar 

  93. Yoshikawa N, Iijima K, Matsuyama S, Suzuki J, Kameda A, Okada S, et al. Repeat renal biopsy in children with IgA nephropathy. Clin Nephrol. 1990;33(4):160–7.

    CAS  PubMed  Google Scholar 

  94. Shima Y, Nakanishi K, Kamei K, Togawa H, Nozu K, Tanaka R, et al. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant. 2011;26(1):163–9.

    CAS  PubMed  Google Scholar 

  95. Ikezumi Y, Suzuki T, Imai N, Ueno M, Narita I, Kawachi H, et al. Histological differences in new-onset IgA nephropathy between children and adults. Nephrol Dial Transplant. 2006;21(12):3466–74.

    PubMed  Google Scholar 

  96. Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant. 2008;23:2537–45.

    PubMed  Google Scholar 

  97. Haas M, Reich HN. Morphologic markers of progressive immunoglobulin A nephropathy. Adv Chronic Kidney Dis. 2012;19(2):107–13.

    PubMed  Google Scholar 

  98. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45.

    PubMed  Google Scholar 

  99. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–56.

    PubMed  Google Scholar 

  100. Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–21.

    PubMed  Google Scholar 

  101. Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77(10):921–7.

    CAS  PubMed  Google Scholar 

  102. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011;80(3):310–7.

    PubMed  Google Scholar 

  103. Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ, Chen YQ, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol. 2011;6(9):2175–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  104. Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011;6(12):2806–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Edstrom Halling S, Soderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant. 2012;27(2):715–22.

    PubMed  Google Scholar 

  106. Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Hashimura Y, et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol. 2012;27(5):783–92.

    PubMed  Google Scholar 

  107. Zeng CH, Le W, Ni Z, Zhang M, Miao L, Luo P, et al. A multicenter application and evaluation of the Oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis. 2012;60(5):812–20.

    PubMed  Google Scholar 

  108. Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011;6(10):2384–8.

    PubMed  PubMed Central  Google Scholar 

  109. Wu H, Xia Z, Gao C, Zhang P, Yang X, Wang R, et al. The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome – a retrospective cohort study. BMC Nephrol. 2020;21(1):247.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Coppo R, D’Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, et al. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford classification for IgA nephropathy (VALIGA) update. Nephrol Dial Transplant. 2020;35(6):1002–9.

    CAS  PubMed  Google Scholar 

  111. Shima Y, Nakanishi K, Hama T, Sato M, Mukaiyama H, Togawa H, et al. Biopsy timing and Oxford classification variables in childhood/adolescent IgA nephropathy. Pediatr Nephrol. 2015;30(2):293–9.

    PubMed  Google Scholar 

  112. Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942–52.

    PubMed  PubMed Central  Google Scholar 

  113. Barbour SJ, Coppo R, Er L, Russo ML, Liu ZH, Ding J, et al, International IgA Nephropathy Network. Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int. 2020;S0085-2538(20):31385.

    Google Scholar 

  114. D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64(245):709–27.

    PubMed  Google Scholar 

  115. Michalk D, Waldherr R, Seelig HP, Weber HP, Scharer K. Idiopathic mesangial IgA-glomerulonephritis in childhood. Description of 19 pediatric cases and review of the literature. Eur J Pediatr. 1980;134(1):13–22.

    CAS  PubMed  Google Scholar 

  116. Linne T, Aperia A, Broberger O, Bergstrand A, Bohman SO, Rekola S. Course of renal function in IgA glomerulonephritis in children and adolescents. Acta Paediatr Scand. 1982;71(5):735–43.

    CAS  PubMed  Google Scholar 

  117. Levy M, Gonzalez-Burchard G, Broyer M, Dommergues JP, Foulard M, Sorez JP, et al. Berger’s disease in children. Natural history and outcome. Medicine. 1985;64(3):157–80.

    CAS  PubMed  Google Scholar 

  118. A multicenter study of IgA nephropathy in children. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int. 1982;22(6):643–52.

    Google Scholar 

  119. Emancipator SN, Gallo GR, Lamm ME. IgA nephropathy: perspectives on pathogenesis and classification. Clin Nephrol. 1985;24(4):161–79.

    CAS  PubMed  Google Scholar 

  120. Ueda Y, Sakai O, Yamagata M, Kitajima T, Kawamura K. IgA glomerulonephritis in Japan. Contrib Nephrol. 1975;4:37–47.

    CAS  PubMed  Google Scholar 

  121. Nakamoto Y, Asano Y, Dohi K, Fujioka M, Iida H, Kida H, et al. Primary IgA glomerulonephritis and Schonlein-Henoch purpura nephritis: clinicopathological and immunohistological characteristics. Q J Med. 1978;47(188):495–516.

    CAS  PubMed  Google Scholar 

  122. Silva FG, Hogg RJ. IgA nephropathy. In: Tisher CC, Brenner BM, editors. Renal pathology: with clinical and functional correlations. Philadelphia: Lippincott; 1989. p. 434–93.

    Google Scholar 

  123. Abuelo JG, Esparza AR, Matarese RA, Endreny RG, Carvalho JS, Allegra SR. Crescentic IgA nephropathy. Medicine. 1984;63(6):396–406.

    CAS  PubMed  Google Scholar 

  124. Hastings MC, Moldoveanu Z, Suzuki H, Berthoux F, Julian BA, Sanders JT, et al. Biomarkers in IgA nephropathy: relationship to pathogenetic hits. Expert Opin Med Diagn. 2013;7(6):615–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  125. Bagchi S, Lingaiah R, Mani K, Barwad A, Singh G, Balooni V, et al. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: a case control study. PLoS One. 2019;14(3):e0214256.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119(6):1668–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  127. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23(9):1579–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One. 2014;9(5):e98081.

    PubMed  PubMed Central  Google Scholar 

  129. Schena FP, Serino G, Sallustio F, Falchi M, Cox SN. Omics studies for comprehensive understanding of immunoglobulin A nephropathy: state-of-the-art and future directions. Nephrol Dial Transplant. 2018;33(12):2101–12.

    CAS  PubMed  Google Scholar 

  130. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005;67(6):2313–20.

    CAS  PubMed  Google Scholar 

  131. Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis. 2007;28(23):4469–83.

    CAS  PubMed  Google Scholar 

  132. Julian BA, Wittke S, Haubitz M, Zurbig P, Schiffer E, McGuire BM, et al. Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases. World J Urol. 2007;25(5):467–76.

    CAS  PubMed  Google Scholar 

  133. Rocchetti MT, Centra M, Papale M, Bortone G, Palermo C, Centonze D, et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics. 2008;8(1):206–16.

    CAS  PubMed  Google Scholar 

  134. Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Shonlein purpura nephritis? Kidney Int. 2001;59(3):823–34.

    CAS  PubMed  Google Scholar 

  135. Habib R, Niaudet P, Levy M. Schonlein-Henoch purpura nephritis and IgA nephropathy. In: Tisher CBB, editor. Renal pathology: with clinical and functional correlations. 2nd ed. Philadelphia: J.B. Lippincott; 1994. p. 472–523.

    Google Scholar 

  136. Yoshikawa N, Nakanishi K, Iijima K. Henoch-Schonlein purpura. In: Neilson EG, Couser WG, editors. Immunologic renal diseases. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1127–40.

    Google Scholar 

  137. Levy M. Do genetic factors play a role in Berger’s disease? Pediatr Nephrol. 1987;1(3):447–54.

    CAS  PubMed  Google Scholar 

  138. Meadow SR, Scott DG. Berger disease: Henoch-Schonlein syndrome without the rash. J Pediatr. 1985;106(1):27–32.

    CAS  PubMed  Google Scholar 

  139. Araque A, Sanchez R, Alamo C, Torres N, Praga M. Evolution of immunoglobulin A nephropathy into Henoch-Schonlein purpura in an adult patient. Am J Kidney Dis. 1995;25(2):340–2.

    CAS  PubMed  Google Scholar 

  140. Silverstein DM, Greifer I, Folkert V, Bennett B, Corey HE, Spitzer A. Sequential occurrence of IgA nephropathy and Henoch-Schonlein purpura: support for common pathogenesis. Pediatr Nephrol. 1994;8(6):752–3.

    CAS  PubMed  Google Scholar 

  141. Weiss JH, Bhathena DB, Curtis JJ, Lucas BA, Luke RG. A possible relationship between Henoch-Schonlein syndrome and IgA nephropathy (Berger’s disease). An illustrative case. Nephron. 1978;22(4–6):582–91.

    CAS  PubMed  Google Scholar 

  142. Yoshikawa N, Ito H, Yoshiya K, Nakahara C, Yoshiara S, Hasegawa O, et al. Henoch-Schoenlein nephritis and IgA nephropathy in children: a comparison of clinical course. Clin Nephrol. 1987;27(5):233–7.

    CAS  PubMed  Google Scholar 

  143. Pouria S, Feehally J. Glomerular IgA deposition in liver disease. Nephrol Dial Transplant. 1999;14(10):2279–82.

    CAS  PubMed  Google Scholar 

  144. Kalsi J, Delacroix DL, Hodgson HJ. IgA in alcoholic cirrhosis. Clin Exp Immunol. 1983;52(3):499–504.

    CAS  PubMed  PubMed Central  Google Scholar 

  145. Sancho J, Egido J, Sanchez-Crespo M, Blasco R. Detection of monomeric and polymeric IgA containing immune complexes in serum and kidney from patients with alcoholic liver disease. Clin Exp Immunol. 1982;47(2):327–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  146. Habib R, Girardin E, Gagnadoux MF, Hinglais N, Levy M, Broyer M. Immunopathological findings in idiopathic nephrosis: clinical significance of glomerular “immune deposits”. Pediatr Nephrol. 1988;2(4):402–8.

    CAS  PubMed  Google Scholar 

  147. Droz D, Kramar A, Nawar T, Noel LH. Primary IgA nephropathy: prognostic factors. Contrib Nephrol. 1984;40:202–7.

    CAS  PubMed  Google Scholar 

  148. D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36(2):227–37.

    PubMed  Google Scholar 

  149. Glassock RJ, Adler SG, Ward HJ, Cohen AH. Primary glomerular diseases. In: Brenner BM, Rector FCJ, editors. The kidney. 4th ed. Philadelphia: Saunders; 1991. p. 1182–279.

    Google Scholar 

  150. Hood SA, Velosa JA, Holley KE, Donadio JV Jr. IgA–IgG nephropathy: predictive indices of progressive disease. Clin Nephrol. 1981;16(2):55–62.

    CAS  PubMed  Google Scholar 

  151. Kobayashi Y, Tateno S, Hiki Y, Shigematsu H. IgA nephropathy: prognostic significance of proteinuria and histological alterations. Nephron. 1983;34(3):146–53.

    CAS  PubMed  Google Scholar 

  152. Katz A, Walker JF, Landy PJ. IgA nephritis with nephrotic range proteinuria. Clin Nephrol. 1983;20(2):67–71.

    CAS  PubMed  Google Scholar 

  153. Chida Y, Tomura S, Takeuchi J. Renal survival rate of IgA nephropathy. Nephron. 1985;40(2):189–94.

    CAS  PubMed  Google Scholar 

  154. Neelakantappa K, Gallo GR, Baldwin DS. Proteinuria in IgA nephropathy. Kidney Int. 1988;33(3):716–21.

    CAS  PubMed  Google Scholar 

  155. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38(4):728–35.

    CAS  PubMed  Google Scholar 

  156. Hattori S, Karashima S, Furuse A, Terashima T, Hiramatsu M, Murakami M, et al. Clinicopathological correlation of IgA nephropathy in children. Am J Nephrol. 1985;5(3):182–9.

    CAS  PubMed  Google Scholar 

  157. Shima Y, Nakanishi K, Sato M, Hama T, Mukaiyama H, Togawa H, et al. IgA nephropathy with presentation of nephrotic syndrome at onset in children. Pediatr Nephrol. 2017;32(3):457–65.

    PubMed  Google Scholar 

  158. Higa A, Shima Y, Hama T, Sato M, Mukaiyama H, Togawa H, et al. Long-term outcome of childhood IgA nephropathy with minimal proteinuria. Pediatr Nephrol. 2015;30(12):2121–7.

    PubMed  Google Scholar 

  159. D’Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Barbiano di Belgioioso G, et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med. 1986;59(228):363–78.

    PubMed  Google Scholar 

  160. Schena FP, Cerullo G, Rossini M, Lanzilotta SG, D’Altri C, Manno C. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol. 2002;13(2):453–60.

    PubMed  Google Scholar 

  161. D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, Fogazzi G, Ferrario F, et al. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine. 1985;64(1):49–60.

    PubMed  Google Scholar 

  162. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29(6):829–42.

    CAS  PubMed  Google Scholar 

  163. Shima Y, Nakanishi K, Hama T, Mukaiyama H, Sato M, Tanaka Y, Tanaka R, et al. Crescentic IgA nephropathy in children. Pediatr Nephrol. 2020;35(6):1005–14.

    PubMed  Google Scholar 

  164. Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, et al. Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol. 2008;23:905–12.

    PubMed  PubMed Central  Google Scholar 

  165. Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, et al. Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol. 2013;28(1):71–6.

    PubMed  Google Scholar 

  166. Kim Y, Yeo SM, Kang SS, Park WY, Jin K, Park SB, et al. Long-term clinical outcomes of first and second kidney transplantation in patients with biopsy-proven IgA nephropathy. Transplant Proc. 2017;49:992–6.

    CAS  PubMed  Google Scholar 

  167. Cattran DC, Feehally J, Terence Cook H, Liu ZH, Fervenza FC, Mezzano SA, Floege J, Nachman PH, Gipson DS, Praga M, Glassock RJ, Radhakrishnan J, Hodson EM, Rovin BH, Jha V, Troyanov S, Kam Tao Li P, Wetzels JFM. Kidney Disease: Improving Global Outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2012;2(Suppl 2):139–274.

    Google Scholar 

  168. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880–8.

    CAS  PubMed  Google Scholar 

  169. Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578–83.

    CAS  PubMed  Google Scholar 

  170. Shima Y, Nakanishi K, Sako M, Saito-Oba M, Hamasaki Y, Hataya H, et al. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Pediatr Nephrol. 2019;34(5):837–46.

    PubMed  Google Scholar 

  171. Bhattacharjee R, Filler G. Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol. 2002;17(4):302–4.

    PubMed  Google Scholar 

  172. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.

    CAS  PubMed  Google Scholar 

  173. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24:3694–701.

    CAS  PubMed  Google Scholar 

  174. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53:26–32.

    CAS  PubMed  Google Scholar 

  175. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.

    CAS  PubMed  Google Scholar 

  176. Coppo R. Pediatric IgA nephropathy: clinical and therapeutic perspectives. Semin Nephrol. 2008;28(1):18–26.

    PubMed  Google Scholar 

  177. Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373:2225–36.

    CAS  PubMed  Google Scholar 

  178. Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;S0085-2538(20):30549–4.

    Google Scholar 

  179. Coppo R. Corticosteroids in IgA nephropathy: lessons from recent studies. J Am Soc Nephrol. 2017;28:25–33.

    CAS  PubMed  Google Scholar 

  180. Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318:432–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  181. Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):268–80.

    PubMed  Google Scholar 

  182. Waldo FB, Alexander R, Wyatt RJ, Kohaut EC. Alternate-day prednisone therapy in children with IgA-associated nephritis. Am J Kidney Dis. 1989;13:55–60.

    CAS  PubMed  Google Scholar 

  183. Welch TR, Fryer C, Shely E, Witte DP, Quinlan M. Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr. 1992;121:474–7.

    CAS  PubMed  Google Scholar 

  184. Niaudet P, Murcia I, Beaufils H, Broyer M, Habib R. Primary IgA nephropathies in children: prognosis and treatment. Adv Nephrol Necker Hosp. 1993;22:121–40.

    CAS  PubMed  Google Scholar 

  185. Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006;1(3):467–74.

    CAS  PubMed  Google Scholar 

  186. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol. 1999;10:101–9.

    CAS  PubMed  Google Scholar 

  187. Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1301–7.

    PubMed  PubMed Central  Google Scholar 

  188. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1(3):511–7.

    CAS  PubMed  Google Scholar 

  189. Shima Y, Nakanishi K, Kaku Y, Ishikura K, Hataya H, Matsuyama T, et al. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT. Pediatr Nephrol. 2018;33(11):2103–12.

    PubMed  Google Scholar 

  190. Yoshikawa N, Nakanishi K, Ishikura K, Hataya H, Iijima K, Honda M, Japanese Pediatric IgA Nephropathy Treatment Study Group. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2008;23(5):757–63.

    PubMed  Google Scholar 

  191. Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, et al. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. J Nephrol. 2013;26(1):86–93.

    CAS  PubMed  Google Scholar 

  192. Cambier A, Rabant M, Peuchmaur M, Hertig A, Deschenes G, Couchoud C, et al. Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features. Kidney Int Rep. 2018;3:916–25.

    PubMed  PubMed Central  Google Scholar 

  193. Du B, Jia Y, Zhou W, Min X, Miao L, Cui W. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis. BMC Nephrol. 2017;18:245.

    PubMed  PubMed Central  Google Scholar 

  194. Hou JH, Le WB, Chen N, Liu ZS, Liu D, Chen JH, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017;69(6):788–95.

    CAS  PubMed  Google Scholar 

  195. Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza F, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis. 2015;66(5):783–91.

    CAS  PubMed  Google Scholar 

  196. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002;13(1):142–8.

    CAS  PubMed  Google Scholar 

  197. Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306–13.

    CAS  PubMed  Google Scholar 

  198. Song YH, Cai GY, Xiao YF, Wang YP, Yuan BS, Xia YY, et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol. 2017;18(1):61.

    PubMed  PubMed Central  Google Scholar 

  199. Feehally J, Coppo R, Troyanov S, Bellur SS, Cattran D, Cook T, et al. Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy. Nephron. 2016;132(1):15–24.

    CAS  PubMed  Google Scholar 

  200. Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29(8):1546–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  201. Matsumoto K, Ikeda Y, Yamaguchi S, Sanematsu M, Fukuda M, Takashima T, et al. Long-term outcomes of tonsillectomy for IgA nephropathy patients: a retrospective cohort study, two-centre analysis with the inverse probability therapy weighting method. Nephrology. 2018;23(9):846–54.

    PubMed  Google Scholar 

  202. Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC, North American IgA Nephropathy Study Group. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol. 2006;1(6):1167–72.

    CAS  PubMed  Google Scholar 

  203. Smerud HK, Bárány P, Lindström K, Fernström A, Sandell A, Påhlsson P, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011;26:3237–42.

    CAS  PubMed  Google Scholar 

  204. Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, et al, NEFIGAN Trial Investigators. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389:2117–27.

    Google Scholar 

  205. Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019;74(1):15–22.

    CAS  PubMed  Google Scholar 

  206. Selvaskandan H, Cheung CK, Muto M, Barratt J. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019;23(5):577–88.

    PubMed  PubMed Central  Google Scholar 

  207. Coppo R. Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr Nephrol. 2020; https://doi.org/10.1007/s00467-020-04486-7.

  208. Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016;68:392–401.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research Center, Takatsuki General Hospital, Osaka, Japan

    Norishige Yoshikawa

  2. Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy

    Rosanna Coppo

Authors
  1. Norishige Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosanna Coppo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norishige Yoshikawa .

Editor information

Editors and Affiliations

  1. Division of Nephrology, Department of Pediatric Specialties, Bambino Gesù Children’s Hospital – IRCCS, Rome, Italy

    Francesco Emma

  2. Division of Nephrology and Hypertension, The Heart Institute, Cincinnati Children’s Hospital Medical Center, College of Medicine, Cincinnati, OH, USA

    Stuart L. Goldstein

  3. Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

    Arvind Bagga

  4. Division of Pediatric Nephrology, UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Carlton M. Bates

  5. Department of Paediatric Nephrology, Great Ormond Street Hospital for Children, NHS Foundation Trust and University College London Institute of Child Health, London, UK

    Rukshana Shroff

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Yoshikawa, N., Coppo, R. (2022). Immunoglobulin A Nephropathy in Children. In: Emma, F., Goldstein, S.L., Bagga, A., Bates, C.M., Shroff, R. (eds) Pediatric Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-52719-8_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52719-8_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-52718-1

  • Online ISBN: 978-3-030-52719-8

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation